Which has stronger earnings and valuation, ICCM or VRAX?

Virax Biolabs Group has lower revenue, but higher earnings than IceCure Medical. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio IceCure Medical $3.38M 1.76 -$15.06M -$8.52 N/A Virax Biolabs Group $10K 195.20 -$5.02M N/A N/A

Does the media prefer ICCM or VRAX?

In the previous week, Virax Biolabs Group had 1 more articles in the media than IceCure Medical. MarketBeat recorded 3 mentions for Virax Biolabs Group and 2 mentions for IceCure Medical. IceCure Medical's average media sentiment score of 0.91 beat Virax Biolabs Group's score of 0.27 indicating that IceCure Medical is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment IceCure Medical 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Virax Biolabs Group 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral

Do analysts prefer VRAX or NVNO?

Virax Biolabs Group currently has a consensus price target of $25.00, indicating a potential upside of 924.59%. Given Virax Biolabs Group's higher probable upside, equities analysts clearly believe Virax Biolabs Group is more favorable than enVVeno Medical. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Virax Biolabs Group 1 Sell rating(s) 1 Hold rating(s) 1 Buy rating(s) 0 Strong Buy rating(s) 2.00 enVVeno Medical 1 Sell rating(s) 1 Hold rating(s) 0 Buy rating(s) 1 Strong Buy rating(s) 2.33

Which has better valuation and earnings, VRAX or NVNO?

Virax Biolabs Group has higher revenue and earnings than enVVeno Medical. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Virax Biolabs Group $10K 195.20 -$5.02M N/A N/A enVVeno Medical N/A N/A -$19.47M -$19.33 N/A

Is VRAX or NVNO more profitable?

Virax Biolabs Group's return on equity of 0.00% beat enVVeno Medical's return on equity. Company Net Margins Return on Equity Return on Assets Virax Biolabs Group N/A N/A N/A enVVeno Medical N/A -62.28% -56.83%

Do analysts recommend INBS or VRAX?

Virax Biolabs Group has a consensus target price of $25.00, suggesting a potential upside of 924.59%. Given Virax Biolabs Group's stronger consensus rating and higher probable upside, analysts plainly believe Virax Biolabs Group is more favorable than Intelligent Bio Solutions. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Intelligent Bio Solutions 1 Sell rating(s) 1 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.50 Virax Biolabs Group 1 Sell rating(s) 1 Hold rating(s) 1 Buy rating(s) 0 Strong Buy rating(s) 2.00

Which has preferable valuation & earnings, INBS or VRAX?

Virax Biolabs Group has lower revenue, but higher earnings than Intelligent Bio Solutions. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Intelligent Bio Solutions $4.22M 1.35 -$12.43M -$9.02 N/A Virax Biolabs Group $10K 195.20 -$5.02M N/A N/A

Does the media favor INBS or VRAX?

In the previous week, Intelligent Bio Solutions and Intelligent Bio Solutions both had 3 articles in the media. Intelligent Bio Solutions' average media sentiment score of 0.93 beat Virax Biolabs Group's score of 0.27 indicating that Intelligent Bio Solutions is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Intelligent Bio Solutions 1 Very Positive mention(s) 0 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Virax Biolabs Group 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral

Do analysts rate VRAX or SONX?

Virax Biolabs Group currently has a consensus price target of $25.00, suggesting a potential upside of 924.59%. Given Virax Biolabs Group's stronger consensus rating and higher possible upside, research analysts plainly believe Virax Biolabs Group is more favorable than Sonendo. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Virax Biolabs Group 1 Sell rating(s) 1 Hold rating(s) 1 Buy rating(s) 0 Strong Buy rating(s) 2.00 Sonendo 0 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 0.00

Which has better earnings & valuation, VRAX or SONX?

Virax Biolabs Group has higher earnings, but lower revenue than Sonendo. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Virax Biolabs Group $10K 195.20 -$5.02M N/A N/A Sonendo $44.40M 0.16 -$60.92M -$71.12 N/A

Does the media refer more to VRAX or SONX?

In the previous week, Virax Biolabs Group had 2 more articles in the media than Sonendo. MarketBeat recorded 3 mentions for Virax Biolabs Group and 1 mentions for Sonendo. Virax Biolabs Group's average media sentiment score of 0.27 beat Sonendo's score of 0.00 indicating that Virax Biolabs Group is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Virax Biolabs Group 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Sonendo 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral

Which has stronger valuation & earnings, AMIX or VRAX?

Virax Biolabs Group has higher revenue and earnings than Autonomix Medical. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Autonomix Medical N/A N/A -$16.72M -$41.57 N/A Virax Biolabs Group $10K 195.20 -$5.02M N/A N/A

Is AMIX or VRAX more profitable?

Virax Biolabs Group's return on equity of 0.00% beat Autonomix Medical's return on equity. Company Net Margins Return on Equity Return on Assets Autonomix Medical N/A -267.73% -216.75% Virax Biolabs Group N/A N/A N/A

Does the media favor AMIX or VRAX?

In the previous week, Autonomix Medical and Autonomix Medical both had 3 articles in the media. Virax Biolabs Group's average media sentiment score of 0.27 beat Autonomix Medical's score of 0.00 indicating that Virax Biolabs Group is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Autonomix Medical 0 Very Positive mention(s) 1 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Virax Biolabs Group 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral

Virax Biolabs Group (VRAX) Competitors

$2.44 -0.11 (-4.31%)

Closing price 09/24/2026 04:00 PM Eastern

Extended Trading

$2.45 +0.01 (+0.37%)

As of 09/24/2026 07:30 PM Eastern

Compare

VRAX vs. ICCM, NVNO, INBS, SONX, and AMIX

Should you buy Virax Biolabs Group stock or one of its competitors? Virax Biolabs Group's main competitors and comparable companies include IceCure Medical (ICCM), enVVeno Medical (NVNO), Intelligent Bio Solutions (INBS), Sonendo (SONX), and Autonomix Medical (AMIX). Companies are selected based on similarities in market, industry, and size. These companies are all part of the "healthcare equipment" industry.

How does Virax Biolabs Group compare to IceCure Medical?

IceCure Medical (NASDAQ:ICCM) and Virax Biolabs Group (NASDAQ:VRAX) are both small-cap healthcare companies, but which is the superior investment? We will compare the two companies based on the strength of their earnings, analyst recommendations, valuation, profitability, dividends, risk, media sentiment and institutional ownership.

IceCure Medical presently has a consensus price target of $52.50, indicating a potential upside of 2,934.68%. Virax Biolabs Group has a consensus price target of $25.00, indicating a potential upside of 924.59%. Given IceCure Medical's stronger consensus rating and higher possible upside, equities analysts clearly believe IceCure Medical is more favorable than Virax Biolabs Group.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
IceCure Medical	2 Sell rating(s)	0 Hold rating(s)	3 Buy rating(s)	0 Strong Buy rating(s)	2.20
Virax Biolabs Group	1 Sell rating(s)	1 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.00

Virax Biolabs Group has a net margin of 0.00% compared to IceCure Medical's net margin of -427.67%. Virax Biolabs Group's return on equity of 0.00% beat IceCure Medical's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
IceCure Medical	-427.67%	-174.26%	-112.58%
Virax Biolabs Group	N/A	N/A	N/A

In the previous week, Virax Biolabs Group had 1 more articles in the media than IceCure Medical. MarketBeat recorded 3 mentions for Virax Biolabs Group and 2 mentions for IceCure Medical. IceCure Medical's average media sentiment score of 0.91 beat Virax Biolabs Group's score of 0.27 indicating that IceCure Medical is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
IceCure Medical	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Virax Biolabs Group	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

0.6% of IceCure Medical shares are held by institutional investors. Comparatively, 8.6% of Virax Biolabs Group shares are held by institutional investors. 2.4% of IceCure Medical shares are held by insiders. Comparatively, 45.1% of Virax Biolabs Group shares are held by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock will outperform the market over the long term.

Virax Biolabs Group has lower revenue, but higher earnings than IceCure Medical.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
IceCure Medical	$3.38M	1.76	-$15.06M	-$8.52	N/A
Virax Biolabs Group	$10K	195.20	-$5.02M	N/A	N/A

IceCure Medical has a beta of 0.45, meaning that its share price is 55% less volatile than the broader market. Comparatively, Virax Biolabs Group has a beta of 1.37, meaning that its share price is 37% more volatile than the broader market.

Summary

Virax Biolabs Group beats IceCure Medical on 9 of the 14 factors compared between the two stocks.

How does Virax Biolabs Group compare to enVVeno Medical?

Virax Biolabs Group (NASDAQ:VRAX) and enVVeno Medical (NASDAQ:NVNO) are both small-cap healthcare companies, but which is the better business? We will compare the two companies based on the strength of their risk, institutional ownership, media sentiment, profitability, earnings, valuation, dividends and analyst recommendations.

Virax Biolabs Group has a beta of 1.37, suggesting that its stock price is 37% more volatile than the broader market. Comparatively, enVVeno Medical has a beta of 1.06, suggesting that its stock price is 6% more volatile than the broader market.

8.6% of Virax Biolabs Group shares are owned by institutional investors. Comparatively, 34.7% of enVVeno Medical shares are owned by institutional investors. 45.1% of Virax Biolabs Group shares are owned by insiders. Comparatively, 15.0% of enVVeno Medical shares are owned by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company will outperform the market over the long term.

Virax Biolabs Group has higher revenue and earnings than enVVeno Medical.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Virax Biolabs Group	$10K	195.20	-$5.02M	N/A	N/A
enVVeno Medical	N/A	N/A	-$19.47M	-$19.33	N/A

In the previous week, Virax Biolabs Group had 2 more articles in the media than enVVeno Medical. MarketBeat recorded 3 mentions for Virax Biolabs Group and 1 mentions for enVVeno Medical. enVVeno Medical's average media sentiment score of 1.79 beat Virax Biolabs Group's score of 0.27 indicating that enVVeno Medical is being referred to more favorably in the news media.

Company	Overall Sentiment
Virax Biolabs Group	Neutral
enVVeno Medical	Very Positive

Virax Biolabs Group currently has a consensus price target of $25.00, indicating a potential upside of 924.59%. Given Virax Biolabs Group's higher probable upside, equities analysts clearly believe Virax Biolabs Group is more favorable than enVVeno Medical.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Virax Biolabs Group	1 Sell rating(s)	1 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.00
enVVeno Medical	1 Sell rating(s)	1 Hold rating(s)	0 Buy rating(s)	1 Strong Buy rating(s)	2.33

Virax Biolabs Group's return on equity of 0.00% beat enVVeno Medical's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Virax Biolabs Group	N/A	N/A	N/A
enVVeno Medical	N/A	-62.28%	-56.83%

Summary

Virax Biolabs Group beats enVVeno Medical on 9 of the 13 factors compared between the two stocks.

How does Virax Biolabs Group compare to Intelligent Bio Solutions?

Intelligent Bio Solutions (NASDAQ:INBS) and Virax Biolabs Group (NASDAQ:VRAX) are both small-cap healthcare companies, but which is the superior business? We will compare the two businesses based on the strength of their profitability, media sentiment, dividends, institutional ownership, analyst recommendations, valuation, earnings and risk.

Intelligent Bio Solutions has a beta of 4.25, indicating that its stock price is 325% more volatile than the broader market. Comparatively, Virax Biolabs Group has a beta of 1.37, indicating that its stock price is 37% more volatile than the broader market.

In the previous week, Intelligent Bio Solutions and Intelligent Bio Solutions both had 3 articles in the media. Intelligent Bio Solutions' average media sentiment score of 0.93 beat Virax Biolabs Group's score of 0.27 indicating that Intelligent Bio Solutions is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Intelligent Bio Solutions	1 Very Positive mention(s)	0 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Virax Biolabs Group	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

Virax Biolabs Group has a net margin of 0.00% compared to Intelligent Bio Solutions' net margin of -294.88%. Virax Biolabs Group's return on equity of 0.00% beat Intelligent Bio Solutions' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Intelligent Bio Solutions	-294.88%	-175.35%	-91.25%
Virax Biolabs Group	N/A	N/A	N/A

Virax Biolabs Group has lower revenue, but higher earnings than Intelligent Bio Solutions.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Intelligent Bio Solutions	$4.22M	1.35	-$12.43M	-$9.02	N/A
Virax Biolabs Group	$10K	195.20	-$5.02M	N/A	N/A

Virax Biolabs Group has a consensus target price of $25.00, suggesting a potential upside of 924.59%. Given Virax Biolabs Group's stronger consensus rating and higher probable upside, analysts plainly believe Virax Biolabs Group is more favorable than Intelligent Bio Solutions.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Intelligent Bio Solutions	1 Sell rating(s)	1 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.50
Virax Biolabs Group	1 Sell rating(s)	1 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.00

33.0% of Intelligent Bio Solutions shares are owned by institutional investors. Comparatively, 8.6% of Virax Biolabs Group shares are owned by institutional investors. 1.3% of Intelligent Bio Solutions shares are owned by company insiders. Comparatively, 45.1% of Virax Biolabs Group shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company is poised for long-term growth.

Summary

Virax Biolabs Group beats Intelligent Bio Solutions on 9 of the 13 factors compared between the two stocks.

How does Virax Biolabs Group compare to Sonendo?

Virax Biolabs Group (NASDAQ:VRAX) and Sonendo (NYSE:SONX) are both small-cap healthcare companies, but which is the superior investment? We will contrast the two businesses based on the strength of their risk, media sentiment, valuation, institutional ownership, earnings, dividends, analyst recommendations and profitability.

Virax Biolabs Group has a beta of 1.37, indicating that its share price is 37% more volatile than the broader market. Comparatively, Sonendo has a beta of 1.81, indicating that its share price is 81% more volatile than the broader market.

8.6% of Virax Biolabs Group shares are held by institutional investors. Comparatively, 28.7% of Sonendo shares are held by institutional investors. 45.1% of Virax Biolabs Group shares are held by company insiders. Comparatively, 7.9% of Sonendo shares are held by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock is poised for long-term growth.

In the previous week, Virax Biolabs Group had 2 more articles in the media than Sonendo. MarketBeat recorded 3 mentions for Virax Biolabs Group and 1 mentions for Sonendo. Virax Biolabs Group's average media sentiment score of 0.27 beat Sonendo's score of 0.00 indicating that Virax Biolabs Group is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Virax Biolabs Group	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
Sonendo	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

Virax Biolabs Group has a net margin of 0.00% compared to Sonendo's net margin of -92.74%. Virax Biolabs Group's return on equity of 0.00% beat Sonendo's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Virax Biolabs Group	N/A	N/A	N/A
Sonendo	-92.74%	-184.01%	-68.60%

Virax Biolabs Group currently has a consensus price target of $25.00, suggesting a potential upside of 924.59%. Given Virax Biolabs Group's stronger consensus rating and higher possible upside, research analysts plainly believe Virax Biolabs Group is more favorable than Sonendo.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Virax Biolabs Group	1 Sell rating(s)	1 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.00
Sonendo	0 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	0.00

Virax Biolabs Group has higher earnings, but lower revenue than Sonendo.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Virax Biolabs Group	$10K	195.20	-$5.02M	N/A	N/A
Sonendo	$44.40M	0.16	-$60.92M	-$71.12	N/A

Summary

Virax Biolabs Group beats Sonendo on 11 of the 14 factors compared between the two stocks.

How does Virax Biolabs Group compare to Autonomix Medical?

Autonomix Medical (NASDAQ:AMIX) and Virax Biolabs Group (NASDAQ:VRAX) are both small-cap healthcare companies, but which is the better investment? We will contrast the two companies based on the strength of their valuation, earnings, risk, profitability, analyst recommendations, institutional ownership, media sentiment and dividends.

Virax Biolabs Group's return on equity of 0.00% beat Autonomix Medical's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Autonomix Medical	N/A	-267.73%	-216.75%
Virax Biolabs Group	N/A	N/A	N/A

Autonomix Medical has a beta of -1, suggesting that its share price is 200% less volatile than the broader market. Comparatively, Virax Biolabs Group has a beta of 1.37, suggesting that its share price is 37% more volatile than the broader market.

Virax Biolabs Group has higher revenue and earnings than Autonomix Medical.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Autonomix Medical	N/A	N/A	-$16.72M	-$41.57	N/A
Virax Biolabs Group	$10K	195.20	-$5.02M	N/A	N/A

Autonomix Medical currently has a consensus target price of $42.00, suggesting a potential upside of 931.94%. Virax Biolabs Group has a consensus target price of $25.00, suggesting a potential upside of 924.59%. Given Autonomix Medical's higher possible upside, equities research analysts clearly believe Autonomix Medical is more favorable than Virax Biolabs Group.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Autonomix Medical	1 Sell rating(s)	1 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.00
Virax Biolabs Group	1 Sell rating(s)	1 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.00

In the previous week, Autonomix Medical and Autonomix Medical both had 3 articles in the media. Virax Biolabs Group's average media sentiment score of 0.27 beat Autonomix Medical's score of 0.00 indicating that Virax Biolabs Group is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Autonomix Medical	0 Very Positive mention(s)	1 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
Virax Biolabs Group	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

10.8% of Autonomix Medical shares are owned by institutional investors. Comparatively, 8.6% of Virax Biolabs Group shares are owned by institutional investors. 5.5% of Autonomix Medical shares are owned by company insiders. Comparatively, 45.1% of Virax Biolabs Group shares are owned by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock is poised for long-term growth.

Summary

Virax Biolabs Group beats Autonomix Medical on 7 of the 9 factors compared between the two stocks.

Get Virax Biolabs Group News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding VRAX and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

VRAX vs. The Competition

Export

Metric	Virax Biolabs Group	Healthcare Equipment & Supplies Industry	Healthcare Sector	NASDAQ Exchange
Market Cap	$1.99M	$5.62B	$7.31B	$13.29B
Dividend Yield	N/A	1.79%	2.52%	12.57%
P/E Ratio	N/A	25.37	274.41	25.76
Price / Sales	195.20	71.00	688.46	106.88
Price / Cash	N/A	33.02	77.80	52.76
Price / Book	0.06	5.74	10.52	6.34
Net Income	-$5.02M	$151.55M	$3.49B	$360.00M
7 Day Performance	-3.94%	-0.42%	-0.94%	-0.16%
1 Month Performance	-16.15%	-4.17%	-4.24%	-4.08%
1 Year Performance	-84.45%	7.44%	16.38%	5.97%

Virax Biolabs Group Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
VRAX Virax Biolabs Group	1.5771 of 5 stars	$2.44 -4.3%	$25.00 +924.6%	-84.7%	$1.99M	$10K	N/A	26	Short Interest Increase
ICCM IceCure Medical	2.5931 of 5 stars	$2.06 +0.5%	$52.50 +2,448.5%	-94.5%	$7.02M	$3.38M	N/A	60
NVNO enVVeno Medical	1.5009 of 5 stars	$9.05 -2.9%	N/A	-73.3%	$6.48M	N/A	N/A	30
INBS Intelligent Bio Solutions	1.0255 of 5 stars	$1.97 -3.9%	N/A	-87.4%	$6.21M	$4.22M	N/A	10	Short Interest Increase
SONX Sonendo	N/A	$1.30 flat	N/A	+500.0%	$6.21M	$44.40M	N/A	250	Gap Down

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:VRAX) was last updated on 9/25/2026 by MarketBeat.com Staff.

From Our Partners

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Virax Biolabs Group (VRAX) Competitors

VRAX vs. ICCM, NVNO, INBS, SONX, and AMIX

How does Virax Biolabs Group compare to IceCure Medical?

Summary

How does Virax Biolabs Group compare to enVVeno Medical?

Summary

How does Virax Biolabs Group compare to Intelligent Bio Solutions?

Summary

How does Virax Biolabs Group compare to Sonendo?

Summary

How does Virax Biolabs Group compare to Autonomix Medical?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

VRAX vs. The Competition

Virax Biolabs Group Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Virax Biolabs Group (VRAX) Competitors

VRAX vs. ICCM, NVNO, INBS, SONX, and AMIX

How does Virax Biolabs Group compare to IceCure Medical?

Do analysts prefer ICCM or VRAX?

Is ICCM or VRAX more profitable?

Does the media prefer ICCM or VRAX?

Do insiders & institutionals have more ownership in ICCM or VRAX?

Which has stronger earnings and valuation, ICCM or VRAX?

Which has more volatility & risk, ICCM or VRAX?

Summary

How does Virax Biolabs Group compare to enVVeno Medical?

Which has more risk & volatility, VRAX or NVNO?

Do insiders & institutionals believe in VRAX or NVNO?

Which has better valuation and earnings, VRAX or NVNO?

Does the media refer more to VRAX or NVNO?

Do analysts prefer VRAX or NVNO?

Is VRAX or NVNO more profitable?

Summary

How does Virax Biolabs Group compare to Intelligent Bio Solutions?

Which has more risk & volatility, INBS or VRAX?

Does the media favor INBS or VRAX?

Is INBS or VRAX more profitable?

Which has preferable valuation & earnings, INBS or VRAX?

Do analysts recommend INBS or VRAX?

Do institutionals & insiders hold more shares of INBS or VRAX?

Summary

How does Virax Biolabs Group compare to Sonendo?

Which has more volatility and risk, VRAX or SONX?

Do insiders & institutionals believe in VRAX or SONX?

Does the media refer more to VRAX or SONX?

Is VRAX or SONX more profitable?

Do analysts rate VRAX or SONX?

Which has better earnings & valuation, VRAX or SONX?

Summary

How does Virax Biolabs Group compare to Autonomix Medical?

Is AMIX or VRAX more profitable?

Which has more volatility & risk, AMIX or VRAX?

Which has stronger valuation & earnings, AMIX or VRAX?

Do analysts rate AMIX or VRAX?

Does the media favor AMIX or VRAX?

Do insiders and institutionals hold more shares of AMIX or VRAX?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

VRAX vs. The Competition

Virax Biolabs Group Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools